7-Dimethylamino-6-demethyl-6-deoxytetracycline, HCl Dark yellow solid. Semi-synthetic tetracycline derivative effective against tetracycline-resistant staphylococci. A matrix metalloproteinase (MMP) inhibitor shown to inhibit tumor-induced angiogenesis. Inhibits stromelysin (MMP-3; IC50 = 290 µM) but does not inhibit other MMPs such as fibroblast collagenase or gelatinase. Potently inhibits PARP-1 (Ki = 13.4 nM) in a NAD+ - competitive manner. Exhibits anti-inflammatory effects and suppresses T cell proliferation. Purity: ≥98% by TLC. RTECS QI7630500, CAS 13614-98-7. Merck Index: 14, 6202
Ref.: Conrad, C.A., et al. 2006. Proc. Natl. Acad, Sci. USA 103, 9685. Gilbertson-Breading, S., et al. 1995. Cancer Chemother. Pharmacol. 36, 418. Kloppenburg, M., et al. 1995. Clin. Exp. Immunol. 102, 635. Preus, H.R., et al. 1995. J. Clin. Periodontol. 22, 380. Weingart, J.D., et al. 1995. J. Neurosurg. 82, 635. Tamargo, R.J., et al. 1991. Cancer Res. 51, 672.
R: 33-36/37/38-63-64; S: 22-45-36 |
